Development of inhibitors for protein tyrosine kinases (Q34103669)

31 July 2017

1 reference

title

Development of inhibitors for protein tyrosine kinases (English)

1 reference

31 July 2017

Al-Obeidi FA

1

1 reference

31 July 2017

Lam KS

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 November 2000

1 reference

31 July 2017

1 reference

31 July 2017

19

1 reference

31 July 2017

49

1 reference

31 July 2017

5690-5701

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1203926

31 July 2017

0 references

cites work

Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

A solid-phase assay for the determination of protein tyrosine kinase activity of c-src using scintillating microtitration plates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Crystal structure of the tyrosine kinase domain of the human insulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

SH2-directed ligands of the Lck tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Protein tyrosine kinase inhibitors as novel therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Tyrosine kinase inhibition: an approach to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Different early effets of tyrphostin AG957 and geldanamycins on mitogen-activated protein kinase and p120cbl phosphorylation in anti CD-3-stimulated T-lymphoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Identification of GIYWHHY as a novel peptide substrate for human p60c-src protein tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2'-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Chromosomal translocations in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

A tyrosine kinase profile of prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

The pathogenesis of atherosclerosis: a perspective for the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Catalytic specificity of phosphotyrosine kinases Blk, Lyn, c-Src and Syk as assessed by phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Crystal structure of the Src family tyrosine kinase Hck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Catalytic specificity of protein-tyrosine kinases is critical for selective signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Molecular scaffold-based design and comparison of combinatorial libraries focused on the ATP-binding site of protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Herceptin (trastuzamab) in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Tyrosine kinase inhibitors as antiproliferative agents against an estrogen-dependent breast cancer cell line in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Comparison of the intrinsic kinase activity and substrate specificity of c-Abl and Bcr-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Three-dimensional structure of the tyrosine kinase c-Src

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Atomic structure of the MAP kinase ERK2 at 2.3 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

21 January 2018

One gene—four syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Measurement of the protein tyrosine kinase activity of c-src using time-resolved fluorometry of europium chelates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

The development and therapeutic potential of protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Overexpression of transforming growth factor alpha in psoriatic epidermis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Combinatorial chemistry as a tool for drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Design of a potent peptide inhibitor of the epidermal growth factor receptor tyrosine kinase utilizing sequences based on the natural phosphorylation sites of phospholipase C-gamma 1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrophostins: potent inhibitors of EGF receptor tyrosine kinase in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Quercetin inhibits tyrosine phosphorylation by the cyclic nucleotide-independent, transforming protein kinase, pp60src

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

The Growth Regulation of Keratinocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Protein tyrosine kinases and cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Identification and characterization of a novel synthetic peptide substrate specific for Src-family protein tyrosine kinases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

A 58-year-old man with sarcoidosis complicated by focal crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Nonphosphorylatable tyrosine surrogates. Implications for protein kinase inhibitor design

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Protein phosphorylation and dephosphorylation in physiologic and oncologic processes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Src homology-2 domains: structure, mechanisms, and drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

A homogeneous, fluorescence polarization assay for src-family tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203926

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1203926

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference